Home / Companies / News / Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis

Glenmark Pharma gets USFDA nod for drug to treat multiple sclerosis

The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis

Premium

Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA

Press Trust of India New Delhi

1 min read Last Updated : Jun 19 2020 | 12:31 PM IST

Drug major Glenmark Pharmaceuticals on Friday said it has received final nod from the health regulator for Fingolimod capsules.

The capsules are used in the treatment of adult patients with relapsing forms of multiple sclerosis.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.

ALSO READ: Sun Pharma, Hikma ink pact for plaque psoriasis drug for MENA region

According to IQVIA sales data for the 12-month period

Topics : Glenmark Pharmaceuticals USFDA Pharma sector

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in